{"id":"W4246797495","doi":"10.1016/j.annonc.2020.10.024","title":"3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"EMD Serono; Samsung; Genentech; PharmaMar; Chugai Pharmaceutical; Vifor Pharma; Astellas Pharma; Eisai; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; OncoSec Medical; Mersana Therapeutics; Amgen; Radius Health; Syndax Pharmaceuticals; Queen Mary University of London; Clovis Oncology; Daiichi Sankyo Europe; Servier; Calithera Biosciences; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Ariad Pharmaceuticals; Exelixis; Sanofi; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Baxalta; Flatiron Health; Genomic Health; GlaxoSmithKline","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Breast cancer; Cyclophosphamide; Triple-negative breast cancer; Oncology; Placebo; Phases of clinical research; Neoadjuvant therapy; Gastroenterology; Chemotherapy; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001341815,0.001053459,0.00155439,0.0003347059,0.0004176119,0.001198281,0.001061036,0.001255905,0.005018052],"category_scores_gemma":[0.0007679127,0.000438938,0.001751943,0.0003796679,0.0007574683,0.0008373708,0.0004514797,0.003583089,0.001434897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007166598,"about_ca_system_score_gemma":0.001374151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001316156,"about_ca_topic_score_gemma":0.005965226,"domain_scores_codex":[0.9996387,0.0001529157,0.00001523987,0.00005743135,0.00003326085,0.0001024645],"domain_scores_gemma":[0.9993411,0.0001130514,0.00008099487,0.00006283025,0.00003725993,0.0003647193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5907012,0.06682761,0.0130117,0.001270116,0.002499074,0.0003198933,0.0003235863,0.003278138,0.06874449,0.0004203671,0.01202151,0.2405824],"study_design_scores_gemma":[0.4014095,0.53925,0.03337245,0.0001229386,0.002028541,0.0006854453,0.0001604375,0.001865175,0.008726798,0.0004269487,0.01188062,0.00007111592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832286,0.004619055,0.0008747187,0.001374208,0.0002790221,0.00145673,0.003604733,0.0002367352,0.004326178],"genre_scores_gemma":[0.9683511,0.004602089,0.003309443,0.003106339,0.0003458699,0.002073532,0.01056776,0.0001715202,0.007472318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005018052,"threshold_uncertainty_score":0.01678705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1192136867313162,"score_gpt":0.4494909992734035,"score_spread":0.3302773125420873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}